脂肪生成
胞浆
乙酰辅酶A羧化酶
碳水化合物反应元件结合蛋白
生物化学
脂肪性肝炎
非酒精性脂肪性肝炎
化学
丙酮酸羧化酶
乙酰辅酶A
非酒精性脂肪肝
酶
脂肪肝
脂质代谢
内科学
医学
转录因子
疾病
基因
作者
Lin Yan,Mingkun Yang,Li Huang,Fan Yang,Jiachen Fan,Yulong Qiang,Yu‐Ting Chang,Wenjie Zhou,Leilei Yan,Jie Xiong,Jie Ping,Shizhen Chen,Dong Men,Feng Li
出处
期刊:Cell Reports
[Cell Press]
日期:2023-11-01
卷期号:42 (11): 113453-113453
被引量:2
标识
DOI:10.1016/j.celrep.2023.113453
摘要
Increased de novo lipogenesis (DNL) is a major feature of nonalcoholic steatohepatitis (NASH). None of the drugs targeting the catalytic activity of acetyl-CoA carboxylase (ACC), the rate-limiting enzyme in the DNL process, have been approved by the FDA. Whether cytosolic ACC1 can be regulated spatially remains to be explored. Herein, we find that streptavidin (SA), which is a bacterium-derived tetrameric protein, forms cytosolic condensates and efficiently induces a spatial re-localization of ACC1 in liver cells, concomitant with inhibited lipid accumulation. Both SA tetrameric structure and multivalent protein interaction are required for condensate formation. Interestingly, the condensates are further characterized as gel-like membraneless organelle (SAGMO) and significantly restrict the cytosolic dispersion of ACC1 and fatty acid synthase. Notably, AAV-mediated delivery of SA partially blocks mouse liver DNL and ameliorates NASH without eliciting hypertriglyceridemia. In summary, our study shows that insulating lipogenesis-related proteins by SAGMO might be effective for NASH treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI